We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis, Generics Industry Criticize FDA for Underestimating Burden of Random Suffixes for Biologics
Novartis, Generics Industry Criticize FDA for Underestimating Burden of Random Suffixes for Biologics
Novartis and the Association for Accessible Medicines, formerly known as GPhA, are criticizing the FDA for underestimating the effect that using random suffixes to identify biologics and biosimilars will have on drugmakers, the market and pharmacovigilance.